Free Trial
NASDAQ:JAGX

Jaguar Animal Health Q3 2026 Earnings Results & Report

Jaguar Animal Health logo
$0.42 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.40 -0.02 (-4.73%)
As of 09:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jaguar Animal Health beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$9.23 versus the -$444.2941 consensus estimate, while revenue of $2.34 million fell short of the $4.85 million estimate by $2.51 million.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call Date
Conference Call
8:30 AM ET

Jaguar Animal Health EPS Results

Actual EPS
-$9.23
Consensus EPS
-$444.2941
Beat/Miss
Beat by +$435.0641
One Year Ago EPS
N/A

Jaguar Animal Health Revenue Results

Actual Revenue
$2.34 million
Expected Revenue
$4.85 million
Beat/Miss
Missed by -$2.51 million
YoY Revenue Growth
N/A

Earnings Documents

Jaguar Animal Health Q3 2026 Earnings FAQ

Jaguar Animal Health (NASDAQ:JAGX) reported earnings of -$9.23 per share for Q3 2026, beating the consensus estimate of -$444.2941. The report was announced on Monday, November 16, 2026.

Jaguar Animal Health reported revenue of $2.34 million for Q3 2026, against a consensus estimate of $4.85 million.

Jaguar Animal Health Earnings Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Jaguar Health, Inc.(BOIN:) dropped from S&P TMI Index
See More Jaguar Animal Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jaguar Animal Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jaguar Animal Health and other key companies, straight to your email.

About Jaguar Animal Health

Jaguar Health, Inc., formerly Jaguar Animal Health (NASDAQ:JAGX), develops prescription medicines for gastrointestinal disorders in humans and animals. The company’s research has focused on plant-derived compounds, including crofelemer, which is derived from the Croton lechleri tree.

Jaguar’s animal-health product Canalevia-CA1 received FDA conditional approval for the treatment of chemotherapy-induced diarrhea in dogs. The company also develops and commercializes crofelemer-based medicines for human gastrointestinal conditions.

Jaguar expanded beyond its original animal-health focus through its 2017 merger with Napo Pharmaceuticals, a company developing plant-based medicines for human health. Napo became a Jaguar subsidiary, and the combined company adopted the Jaguar Health name.

View Jaguar Animal Health Profile